Study to Assess SLN124 in Patients With Polycythemia Vera
This is a Phase 1/2, multicenter study with an open-label dose escalation followed by a
randomized placebo controlled and double-blind phase of SLN124 in adult patients with
Polycythemia Vera (PV) to assess the safety, tolerability, efficacy, pharmacokinetic (PK),
...
Age: 18 years - 66+
Gender: All
A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV
A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients with PV
Age: 18 years - 66+
Gender: All
A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera
The study is designed to evaluate the safety and efficacy of rusfertide in subjects with
polycythemia vera (PV) in maintaining hematocrit control and in improving symptoms of PV.
Age: 18 years - 66+
Gender: All
A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera
The main purpose of this study is to evaluate the efficacy of sapablursen in reducing the
frequency of phlebotomy and in improving quality of life assessments in participants with
polycythemia vera.
Age: 18 - 90 years
Gender: All
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
The purpose of this Phase 3 study is to evaluate the efficacy and safety of Luspatercept
compared with placebo in subjects with myeloproliferative neoplasm (MPN)-associated
Myelofibrosis (MF) and anemia on concomitant Janus kinase 2 (JAK2) inhibitor therapy and who
...
Age: 18 years - 66+
Gender: All
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
The purpose of the study is to compare the efficacy of parsaclisib when combined with
ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis.
Age: 18 years - 66+
Gender: All
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib
This is a phase 1b/2 study of KRT-232 combined with ruxolitinib in subjects with MF who have
a suboptimal response after at least 18 weeks of treatment with ruxolitinib. The primary
objective of the study is to determine a recommended phase 2 dose (RP2D) of KRT 232 ...
Age: 18 - 99 years
Gender: All
Hepcidin Mimetic in Patients With Polycythemia Vera
This is a Phase 2 study with an open-label dose escalation phase followed by a blinded
withdrawal phase and an open label extension. The study is designed to monitor the PTG-300
safety profile and to obtain preliminary evidence of efficacy of PTG-300 for the treatme...
Age: 18 years - 66+
Gender: All
A Safety Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib With Concomitant Luspatercept for Subjects With Anemia
This is Single-Arm, Open-Label Efficacy and Safety Trial of Fedratinib in Subjects with DIPSS
(Dynamic International Prognostic Scoring System)-Intermediate or High- Risk Primary
Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV MF), or Post-Essenti...
Age: 18 years - 66+
Gender: All
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
This study (study ID PAC203 North America; PAC303 ex-North America) is evaluating 200 mg BID
of pacritinib compared to physician's choice (P/C) therapy in patients with MF and severe
thrombocytopenia (platelet count <50,000/μL). Approximately 399 patients in total w...
Age: 18 years - 66+
Gender: All
PD-1 Inhibition in Advanced Myeloproliferative Neoplasms
The purpose of this study is to test the effectiveness of a drug called pembrolizumab in
patients with Myeloproliferative Neoplasm (MPN); chronic phase (MF-CP), accelerated phase
(MPN-AP), or blast phase (MF-BP). Myelofibrosis neoplasm (MPN) is a group of diseases of ...
Age: 18 years - 66+
Gender: All
Research Tissue Bank
This study that will allow for the preservation and/or storage of a small portion one or more of the following tissues: - Peripheral blood - Bone marrow - Bone marrow biopsy - A phlebotomized unit of blood - Spleen cells - Toenail clippings This material will be used fo...
Age: 18 years - 66+
Gender: All
Correlative Biomarker Study in Patients With Myeloproliferative Disorders
Researchers will use abnormal blood and/or bone marrow cells, or materials derived from these abnormal cells, like DNA, RNA, protein or plasma, in laboratory studies. Toenail clippings will provide normal material like DNA for comparison with the abnormal material deriv...
Age: 18 years - 66+
Gender: All